To investigate the mechanisms underlying motor hyperactivity, we performed intracisternal injection of 6-hydroxydopamine or endocrine disruptors in rats on postnatal day 5. 
INTRODUCTION
Patients with attention-deficit hyperactivity disorder (ADHD) show inattention, motor hyperactivity, and impulsivity. Although ADHD is known as a developmental disorder, the etiology is not yet clear. To understand the mechanisms of ADHD, a number of studies have been performed in several kinds of animal models showing genetically derived hyperactivity or naturally occurring behavioral variability. Lesion studies and pharmacological treatment were also reported (C) 2004 Freund & Pettman, U.K. (Viggiano, 2003) . Although the mesocorticolimbic dopamine (DA) system has been suggested to be involved in ADHD, whether the DA system is hypo-or hyper-functioning remains to be elucidated. Because treatment with methylphenidate often attenuates hyperactivity (Swanson, 2003) , a hyperkinetic child with neonatal 6-hydroxydopamine (6-OHDA) lesions (Shaywitz, 1976a, b ) is a valuable model of ADHD in view of motor activity. Rats with a deficit in the development of DA neurons show motor hyperactivity during the juvenile period (Davids, 2002a; Heffner, 1982; Shaywitz, 1976a, b; Zhang, 2001) , which can be attenuated by psychostimulants like those used to treat clinical ADHD (Swanson, 1998; Volkow, 2002) .
It has been demonstrated that exposure to environmental chemicals that mimic the action of estrogen disrupts endocrine function (Markey, 2002) . Most of these compounds, the so-called endocrine disruptors (EDs) , are derived from industrial products and have been detected in the human umbilical cord and cord serum (Mori, 2001 ).
Several lines of evidence suggest that estrogen affects the central DA system (Kuppers, 2001 ). However, the effects of EDs on the central nervous system have not been well documented. Therefore, it would be of interest to study the effects of neonatal treatment with EDs on the DA system and on spontaneous motor activity (SMA) in the rat.
To understand the mechanisms underlying motor hyperactivity caused by the lack of a mesoeortieolimbie DA system, we generated neonatal 6-OHDA lesions in the rat. The effects of neonatal treatment with EDs, such as bisphenol A, nonylphenol, p-oetylphenol and diethylhexylphthalate (DEHP), were also studied to examine whether these chemicals can exert effects on brain function, as shown for other environmental chemicals (Palanza, 1999) . Spontaneous motor activity was measured at 4 weeks of age, a juvenile period. The expression of multiple genes was analyzed by the eDNA maeroarray method using a nylon membrane array in the striatum and midbrain. This method provides results that are more reproducible than the microarray, and several groups have applied this method to their studies on the central nervous system (Cho, 2002; Hida, 2003; Napolitano, 2002) and PC12 cells (Foehr, 2000) . lmmunohistochemical studies were also performed for the detection of tyrosine hydroxylase (TH) to examine the integrity of DA neurons in the midbrain.
EXPERIMENTAL

Treatment of animals
The present study was conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals in the National Institute of Advanced Industrial Science and Technology, Japan, and in the National Institute for Environmental Studies, Japan. Female Wistar rats were purchased from Clea Japan (Tokyo, Japan) 2 weeks after becoming pregnant. The rats were individually housed in an acrylic cage at 22C with tap water and laboratory chow (Oriental Yeast Corp., Tokyo, Japan) ad libitum.
The breeding room was illuminated from 07:00 to 19:00 h in 12-h cycles.
Male pups were selected at 5 days after birth. The body weight of the animals was-10 g. Desipramine (Sigma-Aldrich, St. Louis, Missouri, USA), a blocker of noradrenaline (NA) uptake, was administered intraperitoneally at 25 mg/kg body wt to protect adrenergic neurons from the effects of 6-OHDA. Thirty minutes later, the rats received 100 micrograms (488 nmol) of 6-OHDA hydrobromide (Sigma-Aldrich) in 0.9% NaCI containing 0.04% ascorbic acid (10 microliters) intracistemally. For controls, the vehicle was injected under similar conditions. We also performed an intracistemal administration of EDs, purchased from Wako Pure Chemical Ind. (Tokyo, Japan), without desipramine pretreatment. An ED, such as bisphenol A, nonylphenol, p-octylphenol, or DEHP, was dissolved in olive oil (Nacalai Tesque, Kyoto, Japan) to 8.7 mM. The pups received an intracisternal injection of 87 nmol in a volume of 10 microliters. In some experiments, bisphenol A was dissolved from 0.087 to 87 nmol in 10 microliters. For the control, the same volume of olive oil was injected intracisternally under similar conditions. Next, the pups were randomly assigned to lactating dams, 5-7/dams and weaned at 3 weeks of age.
Measurement of spontaneous motor activity
We measured the SMA of 4-5 week-old rats using the Supermex activity-monitoring system (Muromachi Kikai, Tokyo, Japan), as described previously (Ishido, 2002; Masuo, 1995 significance of the differences between values obtained in rats with neonatal treatment and the respective sham-operated controls. According to the two-tailed probability, p < 0.05 was considered statistically significant.
RESULTS
Endogenous catecholamine levels after neonatal treatment with 6-OHDA We injected 6-OHDA intracistemally into the rat at 5 days of age and the catecholamine contents were measured by HPLC-ECD. As shown in Table 1 , neonatal treatment with 6-OHDA significantly decreased the endogenous levels of DA in the frontal cortex, striatum, and other limbic areas containing the nucleus accumbens, septum, and olfactory tubercles in rats at 10 weeks of age. Among these regions, decreases of DA levels were most significant in the striatum. The levels were diminished by 97% in this region. DA contents in the lesioned rats were significantly lower than in the controls by 43% and by 77% in other limbic areas and in the frontal cortex, respectively. The endogenous levels of NA did not show any significant changes in either region.
Effects of neonatal 6-OHDA lesions on SMA in juvenile rats
As shown in Fig. 1 Tables 2 and 3 show altered gene expression in the midbrain and striatum in rats exposed to neonatal treatment with 6-OHDA, bisphenol A, ). Yet, the degree of increment of SMA is lower than that in previous studies (Davids, 2002b; Zhang, 2001 Zhang, , 2002 Multiple gene expression was examined by cDNA macroarray. Each value represents the ratio of gene expression level versus that ofrespective control value. This table lists the genes for which expression was above the threshold (expression ratios differed by more than 1.69 for an increment, less than 0.59 for a decrement) in rats treated with 6-OHDA. All the DA-related genes contained the Atlas Rat 1.2 are also listed. -, no change; ND, not determined since the density of gene expression was too weak to detect an alteration in the expression; Sic, solute carrier family; PDGF, platelet-derived growth factor. Table 2. substantia nigra pars compacta induced by nonylphenol and p-octylphenol. Similar results were found in rats treated with bisphenol A (Ishido, 2004) .
Therefore, these phenols may cause a deficit in the development of mesocorticolimbic DA neurons. Endogenous catecholamine levels should be further measured after these treatments. Furthermore, bisphenol A might induce apoptosis in central neural cells (Oka, 2003) . Bisphenol A and nonylphenol stimulate hydroxy radical generation in the rat striatum (Obata, 2000) . Taken together, neonatal treatment with phenols can cause neuronal cell death by stimulating hydroxy radical formation, as seen in the effects of 6-OHDA (Ferger, 2001) , and 1-methyl-4-phenylpyridinium ion (MPP/) (Obata, 2001 (Swanson, 1998; Volkow, 2002 (Camerer, 2000; Cho, 2002; Goidin, 2000; Hester, 2003) . To investigate the long-lasting effects of neonatal treatments, we measured gene expression at 8 weeks of age, although the hyperactivity caused by 6-OHDA lesions might be attenuated to control levels (Zhang, 2002) . The decrease in gene expression observed here could not be due solely to the lack of DA neurons because we observed enhanced expression in several genes. Moreover, no difference was found between treated and control rats in the yield of RNA/tissue weight or in the integrity of the RNA in brain regions dissected out in the present study.
The effects of 6-OHDA lesions have been well documented; 6-OHDA affects the survival and the maintenance of DA neurons, thus triggering compensatory responses of the DA system. Recent studies with the DNA array technique demonstrated that several genes, including pleiotrophin, glialderived neurotrophic factor, protein kinase A subunit C, and cyclin-dependent kinase 5, were upregulated in the rat striatum after an injection of 6-OHDA into the substantia nigra (Hida, 2003; Napolitano, 2002) . Taken together, the changes in gene expression observed here seem to be due to DA-specific lesions and compensatory mechanisms. We should note, however, that we performed intracisternal injection of 6-OHDA and EDs on postnatal day 5 and motor hyperactivity was observed at 4 weeks of age. In previous studies (Hida, 2003; Napolitano, 2002) , injected into the unilateral substantia nigra in the rat at 4 or 12 weeks of age, which is an animal model of Parkinson's disease. Thus, the present study is not comparable to these previous studies, and it remains to be possible that the changes in gene expression after neonatal treatment with 6-OHDA and EDs are related to the mechanisms underlying motor hyperactivity.
In rats with neonatal 6-OHDA lesions, the expression of Glast was decreased in the mid-brain and enhanced in the striatum. The findings suggest that alterations in Glast, a high-affinity sodiumdependent glial glutamate/aspartate transporter, might play a part in the important role of motor hyperactivity and/or compensatory mechanisms in young adult rats with 6-OHDA lesions. In DEHPtreated rats, however, Glast expression was enhanced in the midbrain with no change in the striatum; other EDs did not cause a change in Glast in either region. In Grin 1, which encodes the NMDA receptor 1, expression was decreased in the midbrain and striatum by 6-OHDA. In the midbrain, nonylphenol and DEHP, but not bisphenol A and p-octylphenol, also caused a decrease in the expression. In the striatum, DEHP also caused a decrease in the expression. The striatum is a region rich in NMDA receptors (Gracy, 1999; Petralia, 1994; Tarazi, 1999) , and corticostriatal glutamatergic neurons stimulate DA release from the striatum (Taber, 1993) via NMDA receptors (Ochi, 1995 (Madras, 2002; Roman, 2001 ). The expression of Datl can be increased in DA neurons that are resistant to 6-OHDA treatment and/or in non-DA elements (Hoffman, 1998 (Counts, 2002) and striatum (Ericson, 1999; Tsuda, 1998) . It was demonstrated that arginine vasopression (Iqbal, 1995) and GRP (Larsen, 1989) are expressed in the substantia nigra. These peptides might be also involved in motor hyperactivity and/or compensatory changes with different roles in the regulation of the mesostriatal system.
We studied gene expression in the midbrain and striatum to investigate mechanisms underlying motor hyperactivity. It was suggested, however, that the frontal cortex and ventral striatum, including the nucleus accumbens, play important roles in behavior and cognition in ADHD (SonugaBarke, 2002; . A defect in neuronal circuits required for reward-guided associative learning and memory formation might be due to a deficit in glutamate-evoked release in the nucleus accumbens in ADHD patients (Russell, 2003) . The frontal cortex can also play an important role in ADHD (Russell, 2002) . Moreover, it was suggested that the altered neurotransmission of noradrenaline and serotonin is involved in ADHD and/or motor hyperactivity (Blanc, 1994; Davids, 2002a 
